Cephalon Inc

Cephalon — Merger or Acquisition (March 2011)

22 slides from Cephalon's merger presentation, Mar 30, 2011

  1. Slide 1: Valeant's Proposed Acquisition of Cephalon Conference Call

    Valeant's Proposed Acquisition of Cephalon Conference Call March 30, 2011

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company"), including, but not limited to, statements regarding our offer to purchase Cephalon, Inc. ("Cephalon"), financ

  3. Slide 3: Agenda

    Agenda Cephalon Key Offer Terms Valeant Overview Cephalon Transaction Timeline - Next Steps

  4. Slide 4: Key Offer Terms

    Key Offer Terms $73 per share in cash This represents a 29% premium to Cephalon's 30-day trading average We are willing to consider raising our original offer if Cephalon agrees to let us perform due diligence We will be disciplined on price Debt financing lined up Disciplined approach Intention is

  5. Slide 5: Strategic Rationale

    Strategic Rationale Transaction consistent with Valeant strategy We value products, not pipeline Significant opportunities Maximize organic growth and cash flow of in-line specialty pharmaceutical products Enhance European branded generic business Apply Valeant Leveraged R&D model to Cephalon pipeli

  6. Slide 6: Valeant Overview

    Valeant Overview Wy VALEANT

  7. Slide 7: Valeant Pharmaceuticals Overview

    Valeant Pharmaceuticals Overview Focused, multinational specialty pharma company Specialty Pharma (U.S., Canada, Australia, New Zealand) Dermatology, Neurology and Other Branded Generics - Central Europe (Poland, Serbia, Hungary, Czech Republic) Branded Generics - Latin America (Mexico, Brazil) Dive

  8. Slide 8: Valeant Strategy

    Valeant Strategy Truly low cost operating structure Do not bet on science, bet on management Avoid the big guys in the areas where they are strong Do not fall in love with your assets - be willing to sell, partner or shut down Be prudent about investing ahead of need Speed is the greatest advantage

  9. Slide 9: Strong Execution Track Record

    Strong Execution Track Record SOURCE: Valeant Valeant Management Team Performance** USD 740% price adjusted increase in companies under current management team (Feb 2008 to today) Consistently exceeded quarterly expectations Total returned to shareholders via repurchases: $850M (shares @ $12.42 aver

  10. Slide 10: Management's Successful M&A Track Record

    Management's Successful M&A Track Record Aton Pharma Biovail/Valeant Merger Blaufarma Bunker Cholestagel Coria Labs Delta DermaTech Dow Pharmaceutical Sciences EMO-FARM Hamilton Suncare Laboratories Dr. Renaud PharmaSwiss Private Formula International Reckitt Benckiser Refissa Tecnofarma Ultravate V

  11. Slide 11: Biovail Integration

    Biovail Integration Integration largely complete 6 months after closing 500+ employees notified, 400+ employees will have left by the end of Q1 2011 Majority of the facility closures completed R&D progress Relevant programs returned to natural owners for continued development None terminated to date

  12. Slide 12: The Transaction

    The Transaction Wy VALEANT

  13. Slide 13: Compelling Value for Cephalon Stockholders

    Compelling Value for Cephalon Stockholders Significant premium compared to recent specialty pharma transactions All cash proposal Higher price than share price has traded past 2 years Analysts skeptical that untested management can deliver value First Call consensus stock price target currently $64.

  14. Slide 14: Cephalon's Multiple is Above Peers Factoring in Patent Cliff

    Cephalon's Multiple is Above Peers Factoring in Patent Cliff IBES EPS Estimates Price / Earnings * *Share price as of close 28-Mar-2011; Peers include Endo, Forest Laboratories, Salix, Warner Chilcott, Watson

  15. Slide 15: Low Pro Forma Leverage

    Low Pro Forma Leverage New debt raised to finance purchase: Cephalon equity $5.7 billion Cephalon converts $1.3 billion Other costs $0.6 billion Less Cephalon cash remaining ($0.9) billion Net = New Debt Raised $6.7 billion Pro Forma Capitalization Current debt $4.5 billion New debt $6.7 billion Tot

  16. Slide 16: Timing is Critical

    Timing is Critical Unsustainable set of assets, earnings and cash flow Patent cliffs Generic competition Cephalon spending cash on risky investments Recent deals - Gemin X and ChemGenex Development pipeline Continued investment in infrastructure No cost cutting in place "...when Provigil goes away,

  17. Slide 17: Research Analysts Say Cephalon's "Lottery" Strategy is Misguided

    Research Analysts says Cephalon's "Lottery" Strategy is Misguided "Despite our assertion that the market is well aware that Cephalon earnings will decline, we do not argue the stock have reached a floor. ...while the pipeline lottery cards are keeping us away from suggesting shorting the stock, they

  18. Slide 18: No Substantive Engagement by Cephalon's Board

    No Substantive Engagement by Cephalon's Board Original offer on March 18 $73 per share all cash proposal Cephalon response: Well below where we would consider selling, but Board will meet...analysts and investors are obsessed with our patent cliffs and don't give us enough credit for our pipeline po

  19. Slide 19: Transaction Process

    Transaction Process Appealing directly to shareholders due to lack of engagement by Cephalon's Board of Directors Prepared to engage in consensual negotiations at any time Intend to promptly commence Consent Solicitation Process during week of April 4 to replace Cephalon's Board of Directors: Notify

  20. Slide 20: Valeant's Transaction Operating Principles

    Valeant's Transaction Operating Principles Our primary objective is shareholder value We do not enter a transaction to win at all costs We are dispassionate in any single deal We do not play games in negotiations or participate in auctions We maximize speed and believe "deal process" creates distrac

  21. Slide 21: What We Ask from Cephalon Stockholders

    What We Ask from Cephalon Stockholders After record date, let your Board know your vote quickly If we have a majority vote, we will move forward quickly - if not, we will move on Friendly Offer to Owners of Cephalon Certain - all cash (potentially higher after due diligence) Immediate - not dependen

  22. Slide 22: Valeant's Proposed Acquisition of Cephalon Conference Call

    Valeant's Proposed Acquisition of Cephalon Conference Call March 30, 2011

Cephalon — Merger or Acquisition (March 2011) on 6ix